Deep Brain Stimulation of Nucleus Accumbens for Chronic and Resistant Major Depressive Disorder

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

6 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-02-28

Study Completion Date

2013-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Depression is a common, recurrent and disabling disorder. Among patients with a chronic course of the disease, 20 to 30% are resistant to antidepressant medications. Among those patients, 50% would not benefit from electroconvulsive therapy (ECT). For such patients, deep brain stimulation (DBS) of nucleus accumbens is considered.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

DBS in Treatment Resistant Major Depression

NCT01268137

Resistant Major Depressive Disorder

UNKNOWN PHASE3

Deep Brain Stimulation in Patients With Chronic Treatment Resistant Depression

NCT01973478

Major Depressive Disorder Recurrent Depressive Disorder Bipolar Disorder

COMPLETED NA

Deep Brain Stimulation in Treatment Resistant Depression

NCT01435148

Treatment Resistant Depression

UNKNOWN NA

Deep Brain Stimulation for Treatment-Refractory Major Depression

NCT00122031

Depression

COMPLETED PHASE1

Deep Brain Stimulation for Treatment Resistant Depression

NCT05716555

Depressive Disorder, Major

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Depression is a common (12-Month Prevalence in the general population: 6%), recurrent and disabling disorder.

Among patients with a chronic course of the disease, 20 to 30% are resistant to antidepressant medications. Among those patients not responding favorably to antidepressant medications, 50% would not benefit from ECT. For such patients, surgical interventions have been proposed in the past.

Many results support the hypothesis of a dysfunction of the functional loops between cortical and subcortical structures underlying the expression of depressive disorders.

Thus, therapeutic intervention focusing on these loops, in patients with chronic depression resistant to treatment, should be an issue and could improve prognosis of these patients.

As part of a maximal resistance to antidepressant drug, after failure of a series of bilateral ECT, a surgical functional intervention using DBS of nucleus accumbens is considered.

This open-label trial proposes to assess feasibility, safety and efficacy of DBS of nucleus accumbens in patients with chronic depression.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Major Depressive Disorder, Recurrent, Unspecified

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Deep brain stimulation

Deep brain stimulation of nucleus accumbens

Intervention Type PROCEDURE

* Day0 : surgical placement of electrodes
* M1 : stimulation of nucleus accumbens
* M5 : stimulation of nucleus accumbens or associative territory of caudate nucleus (if no response observed with nucleus accumbens stimulation)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Deep brain stimulation of nucleus accumbens

* Day0 : surgical placement of electrodes
* M1 : stimulation of nucleus accumbens
* M5 : stimulation of nucleus accumbens or associative territory of caudate nucleus (if no response observed with nucleus accumbens stimulation)

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Non applicable.

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients between 30 and 60 years old
* Meeting DSM-IV-TR for a major depressive disorder (MDD), recurrent (296.3x) diagnosed using the MINI scale
* Duration of the episode \> 2 years
* History of recurrent MDD (at least one prior episode index), authenticated by a report of ambulatory care or hospitalization
* Meeting Thase and Rush stage V for resistance (Thase and Rush 1997) (Annex 1 : mettre l'annexe)
* Presenting simultaneously an HDRS total score (17 items)\> 21, a GAF \<50, and a score of 4 on CGI despite the use of all the following strategies :

* monotherapy: 2 SSRIs, 1 ISRNA, 1 tricyclic (with measurement of plasma) at the maximum prescribed for a period of 8 weeks
* association at least one previous antidepressant, and for at least six weeks of one of the following treatment: lithium, thyroid hormone, buspirone, pindolol. An intolerance to one of these drug treatments related to its known side effects will be considered equivalent to the lack of effect of this treatment
* irreversible MAOI: iproniazid (Marsilid \*)
* combination of 2 antipsychotics, with at least a second generation antipsychotic (olanzapine, risperidone, amisulpride, aripiprazole or clozapine)
* combination of 2 antidepressants
* ECT: at least 8 sessions in maximal load with crisis GET\> 25 sec bilaterally. If not possible by cognitive impairment: unilateral
* structured psychotherapy inspired cognitive-behavioral or other type of structured psychotherapy for a period of one year
* Understanding of the study
* Giving their written, free and informed consent
* Affiliated to social security

Exclusion Criteria

* Serious and unstable medical condition (cardiovascular, respiratory, endocrine, metabolic, liver, renal, hematologic, infectious, neurological or other ...) making impossible the establishment of study treatment
* Cognitive deterioration (Mattis \< 130)
* Abnormal brain standard MRI or contraindication for MRI
* Axis 1 disorder other than MDD (except generalized anxiety disorder, social phobia, panic disorder)
* Addiction to alcohol and other psychoactive substances with the exception of nicotine
* suicide risk in the last month (MINI 5.0.0: section suicide risk DIGS: section intent, premeditation, lethality) and score\> 2 in item 3 of HDRS
* More than two suicide attempts within two years prior to inclusion
* MDD with psychotic features congruent or incongruent to the mood or an history of MDD with psychotic features
* Diagnostic criteria for personality disorders according to DSM-IV-TR Cluster A or B evaluated using the SCID2 (Maffei et al., 1997)
* Involuntary commitment, guardianship or trusteeship
* Women of childbearing without effective contraception

Minimum Eligible Age

30 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No